Trazodone Metabolism
Trazodone is primarily metabolized by CYP3A4 through oxidative cleavage to form its only active metabolite, m-chlorophenylpiperazine (mCPP), with less than 1% excreted unchanged in urine. 1
Primary Metabolic Pathway
The dominant metabolic route involves CYP3A4-mediated oxidative cleavage to produce mCPP, which is the sole pharmacologically active metabolite 1, 2. This has been definitively established through multiple lines of evidence:
- Human liver microsome studies show mCPP formation correlates exclusively with CYP3A4 activity 3
- Recombinant enzyme studies demonstrate only CYP3A4 (not CYP1A1, 1A2, 2C8, 2C9, 2C19, or 2D6) produces mCPP from trazodone 3
- The Km for this reaction is approximately 163-180 μmol/L 4
Secondary Metabolic Pathways
While CYP3A4 dominates, other enzymes contribute to formation of inactive metabolites 2:
- CYP2D6, CYP2C19, and flavin-containing monooxygenases (FMOs) produce other major inactive metabolites including M9 and M2 2
- Hydroxylation on the chlorophenyl residue produces conjugates (representing ~20% of urinary metabolites) 5
- A dihydrodiol metabolite accounts for ~15% of urinary excretion 5
- Oxidative cleavage produces a carboxylic acid (~35% of urinary metabolites) 5
Elimination Characteristics
Elimination half-life: Biphasic with initial phase of 1 hour and terminal phase of 13 hours 5. The drug demonstrates:
- 70-75% renal excretion within 72 hours (primarily as metabolites, not parent drug) 5
- High first-pass metabolism with systemic bioavailability of 10-70% 6
- Extensive metabolism with <1% excreted unchanged 1
- Plasma protein binding of 89-95% 1
Clinically Significant Drug Interactions
High-Risk CYP3A4 Inhibitors (Avoid or Use Extreme Caution)
Ketoconazole is a potent inhibitor with Ki = 0.12 μmol/L, demonstrating competitive inhibition of mCPP formation 4. This represents a major drug interaction risk.
HIV protease inhibitors pose significant interaction risks 4:
- Ritonavir: Ki = 0.14 μmol/L (potent inhibitor)
- Indinavir: Strong inhibitor
- Saquinavir and nelfinavir: Weaker but still clinically relevant inhibitors
These interactions will increase trazodone plasma levels and decrease mCPP formation, potentially leading to:
- Enhanced sedation and CNS depression
- Increased risk of orthostatic hypotension (due to α1-adrenergic antagonism) 1
- Paradoxically reduced antidepressant efficacy at higher doses (due to decreased active metabolite)
CYP3A4 Inducers
Drugs inducing CYP3A4 (rifampin, carbamazepine, phenytoin) will decrease trazodone levels and reduce therapeutic efficacy 6.
Food Effects
Taking trazodone with food increases total absorption but delays and reduces peak concentration 1:
- Peak plasma time shifts from 1 hour (fasted) to 2 hours (fed)
- Maximum concentration decreases by ~30% 5
- This may reduce side effects while maintaining efficacy
Clinical Pitfalls
Interspecies differences are pronounced: Human hepatocytes show the slowest intrinsic clearance compared to rodent models, meaning animal data significantly underestimates human drug exposure 2. This is critical when interpreting preclinical toxicology data.
Genetic polymorphisms: While CYP3A4 shows less dramatic genetic variation than CYP2D6, the guideline notes that genotyping for CYP3A4/5 is clinically available and may be relevant for patients with suspected altered metabolism 6.
Accumulation potential: The FDA label specifically warns that trazodone may accumulate in plasma in some patients 1, necessitating dose adjustments in hepatic insufficiency where metabolism is impaired 6.